{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-087286","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2025-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.393510+00:00","generated_at":"2026-05-17T08:21:36.483719+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Zura Bio files updated corporate presentation for investor meetings","bullets":["Updated corporate presentation dated September 4, 2025, filed as Exhibit 99.1.","Presentation highlights Zura Bio's dual-pathway biologic candidates in autoimmune/inflammatory diseases.","No specific clinical, financial, or guidance changes disclosed; presentation is a routine update.","Ticker ZURA is the sole identifier; no counterparties mentioned."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-087286","json":"https://secwatch.observer/filing/0001104659-25-087286.json","markdown":"https://secwatch.observer/filing/0001104659-25-087286.md","text":"https://secwatch.observer/filing/0001104659-25-087286.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465925087286/0001104659-25-087286-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465925087286/tm2525151d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T08:21:36.483719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}